{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:16:56Z","timestamp":1788239816553,"version":"build-2803163510"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Scrotal Extramammary Paget\u2019s disease (EMPD) is a rare cutaneous adenocarcinoma commonly confined to the intraepidermal region, with potential for dermal invasion and metastasis. This report describes a rare case of metastatic scrotal EMPD with bone-marrow involvement. The patient presented with localized pruritic scrotal lesions accompanied by systemic symptoms resulting from distant metastases to the lymph nodes and multiple bones, as well as compromised hematopoiesis caused by tumor cell infiltration of bone marrow. The diagnosis was confirmed by histopathological examination of biopsy specimens from the scrotal lesion, local lymph nodes, and bone marrow. Immunohistochemistry (IHC) revealed HER2 status as 2+ with a negative fluorescence\n                    <jats:italic>in situ<\/jats:italic>\n                    hybridization result. Although the patient presented with a heavy tumor burden involving the bone marrow, he appeared to derive benefit from trastuzumab deruxtecan (T-DXd), a HER2-directed antibody-drug conjugate, and observed disease stability during the treatment period. This case suggests the potentially aggressive biological behavior of EMPD and demonstrates that targeted therapeutics, such as T-DXd, may achieve disease control in cases with low HER2 expression. These findings emphasize the need for further research to establish optimal treatment strategies for metastatic EMPD.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1886979","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:26:48Z","timestamp":1788236808000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Trastuzumab deruxtecan treatment for HER2-low metastatic scrotal extramammary Paget\u2019s disease with bone marrow involvement: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Yi","family":"Bao","sequence":"first","affiliation":[{"name":"The Department of Oncology, the Second Affiliated Hospital of Jiaxing University","place":["Jiaxing, Zhejiang, China"]},{"name":"The Department of Medicine, the Second Affiliated Hospital of Jiaxing University","place":["Jiaxing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Department of Medicine, the Second Affiliated Hospital of Jiaxing University","place":["Jiaxing, Zhejiang, China"]},{"name":"Department of Geriatric Medicine, the Second Affiliated Hospital of Jiaxing University","place":["Jiaxing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenfen","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine, the Second Affiliated Hospital of Jiaxing University","place":["Jiaxing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanfen","family":"Mo","sequence":"additional","affiliation":[{"name":"The Department of Oncology, the Second Affiliated Hospital of Jiaxing University","place":["Jiaxing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-021-00923-3","article-title":"Current management and treatment of extramammary Paget's disease","volume":"23","author":"Hashimoto","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.7148","article-title":"Evidence-based clinical practice guidelines for extramammary Paget disease","volume":"8","author":"Kibbi","year":"2022","journal-title":"JAMA Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01281-4","article-title":"Trastuzumab deruxtecan: First approval","volume":"80","author":"Keam","year":"2020","journal-title":"Drugs"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11864-018-0545-x","article-title":"Surgical treatment for extramammary Paget's disease","volume":"19","author":"Wollina","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000003736","article-title":"Treatment outcomes of adjunct and stand-alone photodynamic therapy in patients with extramammary Paget disease: A literature review","volume":"49","author":"Sachdeva","year":"2023","journal-title":"Dermatol Surg"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2025.101754","article-title":"Trastuzumab monotherapy as maintenance treatment for metastatic HER2+ vulvar Paget disease: systematic review and case report","volume":"59","author":"Incognito","year":"2025","journal-title":"Gynecol Oncol Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13200","article-title":"Usefulness of docetaxel as first-line chemotherapy for metastatic extramammary Paget's disease","volume":"43","author":"Yoshino","year":"2016","journal-title":"J Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2820","article-title":"Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget's disease","volume":"9","author":"Gatalica","year":"2020","journal-title":"Cancer Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae097","article-title":"Phase II clinical trial of docetaxel and trastuzumab for HER2-positive advanced extramammary Paget's disease (EMPD-HER2DOC)","volume":"29","author":"Hirai","year":"2024","journal-title":"Oncologist"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107695","article-title":"Advances in HER2-targeted therapies: from monoclonal antibodies to dual inhibitors developments in cancer treatment","volume":"151","author":"Bhagyalalitha","year":"2024","journal-title":"Bioorg Chem"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17500","article-title":"Extramammary Paget's disease treated with of anti-programmed cell death protein 1 therapy after docetaxel therapy failure","volume":"52","author":"Narasaki","year":"2025","journal-title":"J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: Camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02992-x","article-title":"Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial","volume":"30","author":"Shitara","year":"2024","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00575","article-title":"Trastuzumab deruxtecan in anti-human epidermal growth factor receptor 2 treatment-naive patients with human epidermal growth factor receptor 2-low gastric or gastroesophageal junction adenocarcinoma: exploratory cohort results in a phase II trial","volume":"41","author":"Yamaguchi","year":"2023","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1886979\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:26:48Z","timestamp":1788236808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1886979\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":18,"alternative-id":["10.3389\/fonc.2026.1886979"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1886979","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"1886979"}}